Funding & Deals
Sep 23, 2026 · 1 min read · 67,599 views
Telix and radioisotope maker ITM merge in deal worth up to $2.35B
E
Ethan Cole
Editorial · Sep 23, 2026
Reports indicate that the merger will combine ITM's commercial radioisotope manufacturing with Telix's radiotherapy pipeline. But some deal milestones hinge on a recently rejected drug
← Previous
A federal AI experiment could transform chronic care - if doctors and patients want it
Next →
Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
